Ben Hohl serves as Chief Financial Officer of Enliven Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for serious oncology indications. In this role, which he assumed in July 2022, Hohl oversees all aspects of the company's financial operations, including strategic planning, financial reporting, treasury management, investor relations, and capital allocation. He played a pivotal role in Enliven's successful initial public offering on Nasdaq in January 2023, raising approximately $214 million to advance the company's lead programs, such as ENL-201 for anaplastic lymphoma kinase-positive cancers. Prior to Enliven, Hohl was Chief Financial Officer at Reata Pharmaceuticals, where he led financial strategy through the company's $7.3 billion acquisition by Biogen in 2023. Previously, he served as Vice President of Finance at Audentes Therapeutics, managing finance during its $3 billion acquisition by Astellas Pharma in 2020. His earlier career includes senior finance positions at Relypsa, Inc. (acquired by Galencia), and other life sciences firms, bringing over 20 years of expertise in biotech financing, mergers and acquisitions, and capital markets. A Chartered Financial Analyst (CFA), Hohl holds a B.S. in Finance from the University of Colorado. His track record of driving value in high-growth biotechs has positioned Enliven for robust pipeline execution and long-term shareholder returns.